Stockscreener 앱 받기
1.605
5.03%
-0.085
시간 외 거래:
1.65
0.045
+2.80%
전일 마감가:
$1.69
열려 있는:
$1.54
하루 거래량:
1.91M
Relative Volume:
1.01
시가총액:
$222.63M
수익:
-
순이익/손실:
$-45.44M
주가수익비율:
-4.5857
EPS:
-0.35
순현금흐름:
$-42.28M
1주 성능:
-23.57%
1개월 성능:
-41.21%
6개월 성능:
-15.53%
1년 성능:
-13.24%
1일 변동 폭
$1.53
$1.695
1주일 범위
$1.33
$2.435
52주 변동 폭
$0.765
$4.08
Compass Therapeutics Inc Stock (CMPX) Company Profile
명칭
Compass Therapeutics Inc
전화
617-500-8099
주소
80 GUEST STREET, BOSTON
CMPX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
1.605 | 222.63M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 125.55B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 67.78B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 36.24B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.99B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.77B | 3.81B | -644.79M | -669.77M | -6.24 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 개시 | Guggenheim | Buy |
| 2025-02-19 | 개시 | Piper Sandler | Overweight |
| 2024-12-23 | 개시 | D. Boral Capital | Buy |
| 2024-11-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | 개시 | Jefferies | Buy |
| 2023-01-27 | 개시 | Stifel | Buy |
| 2022-05-23 | 재개 | H.C. Wainwright | Buy |
| 2022-03-15 | 개시 | Ladenburg Thalmann | Buy |
| 2022-01-19 | 개시 | B. Riley Securities | Buy |
| 2021-12-22 | 개시 | Raymond James | Outperform |
| 2021-12-20 | 개시 | SVB Leerink | Outperform |
| 2021-12-15 | 개시 | Wedbush | Outperform |
모두보기
Compass Therapeutics Inc 주식(CMPX)의 최신 뉴스
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - The Manila Times
Leerink Partners Upgrades Compass Therapeutics (CMPX) - Nasdaq
Compass Therapeutics rises on trial win for biliary tract cancer therapy - MSN
Leerink raises Compass Therapeutics stock rating, PT to $6 from $4 - Investing.com
Compass Therapeutics And 2 More Compelling Penny Stocks - Yahoo Finance
Compass Therapeutics Target of Unusually Large Options Trading (NASDAQ:CMPX) - Defense World
Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from D. Boral Capital - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Compass Therapeutics (NASDAQ:CMPX) Given Outperform Rating at Wedbush - Defense World
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing - GlobeNewswire
Compass Therapeutics price target raised to $11 from $10 at Stifel - MSN
Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer - Yahoo Finance
Clinical Breakthrough Propels Compass Therapeutics (CMPX) Stock Higher - Stocks Telegraph
Compass Therapeutics Reports Positive Phase 2/3 Trial Results For Tovecimig - Nasdaq
Compass Therapeutics touts trial success in biliary tract cancer, but more data are needed - Endpoints News
Compass Therapeutics stock down amid trial win (CMPX:NASDAQ) - Seeking Alpha
Compass Therapeutics falls; brokerage says cancer drug trial data underwhelms - TradingView
Compass Therapeutics Says its Ongoing Biliary Tract Cancer Combination Drug Trial Indicates Statistically Significant Overall Response Rate - MarketScreener
Compass Therapeutics stock rises on trial win (CMPX:NASDAQ) - Seeking Alpha
Compass Therapeutics Reports Positive Phase 2/3 Trial Results - TipRanks
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer - The Manila Times
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Compass Therapeutics to Host Webcast Highlighting Top-Line - GlobeNewswire
Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer - The Manila Times
Compass Therapeutics, Inc.'s (NASDAQ:CMPX) market cap decline of US$44m may not have as much of an impact on institutional owners after a year of 0.5% returns - simplywall.st
Is Compass Therapeutics (CMPX) The Hot Biotech Stock Under $5? - Yahoo
Connor Clark & Lunn Investment Management Ltd. Trims Stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
[Top 3] Best Biotech Penny Stocks to Buy in 2025Finbold - Finbold - Finance in Bold
10 Hot Biotech Stocks Under $5 - Insider Monkey
With 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interest - Yahoo Canada Finance
Gallbladder Neoplasms Treatment Market Size in the 7MM - openPR
Compass Therapeutics (CMPX) Projected to Post Earnings on Thursday - Defense World
Rubicon Technology (NASDAQ:RBCN) Now Covered by Analysts at StockNews.com - Defense World
Heron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to Hold - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Repligen (NASDAQ:RGEN) and Compass Therapeutics (NASDAQ:CMPX) Critical Review - Defense World
Research Analysts Issue Forecasts for CMPX Q1 Earnings - Defense World
Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 - Insider Monkey
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
D. Boral Capital Reiterates "Buy" Rating for Compass Therapeutics (NASDAQ:CMPX) - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Compass Therapeutics shares rise on pipeline progress By Investing.com - Investing.com Canada
Compass Therapeutics shares rise on pipeline progress - Investing.com
Compass Therapeutics Reports 2024 Financial Results - TipRanks
Compass Therapeutics reports Q4 EPS (11c), consensus (9c) - TipRanks
Compass Therapeutics, Inc. SEC 10-K Report - TradingView
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire
D. Boral Capital Reiterates “Buy” Rating for Compass Therapeutics (NASDAQ:CMPX) - Defense World
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Guggenheim - MarketBeat
Guggenheim Initiates Coverage of Compass Therapeutics (CMPX) with Buy Recommendation - Nasdaq
Compass stock gains amid Guggenheim buy rating - MSN
Compass Therapeutics Inc (CMPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):